Search results
Results from the WOW.Com Content Network
1.10 Platinum compounds: Carboplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Ovarian cancer, lung cancer and squamous cell head and neck cancer: Myelosuppression, nausea and vomiting (30-90%), peripheral neuropathy, ototoxicity, anaphylaxis, acute kidney failure (rare), haemolytic uraemic syndrome (rare) and loss of ...
284.9 Aplastic anemia unspecified; 285 Other and unspecified anemias. 285.0 Sideroblastic anemia; 285.1 Acute posthemorrhagic anemia; 285.2 Anemia in chronic illness. 285.21 Anemia in chronic kidney disease; 285.22 Anemia in neoplastic disease; 285.29 Anemia of other chronic illness; 285.3 Antineoplastic chemotherapy induced anemia; 285.8 Other ...
Sugemalimab, sold under the brand name Cejemly among others, is a monoclonal antibody used for the treatment of metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy. [1] It is an antineoplastic monoclonal antibody that potentiates T-cell responses, including anti-tumor responses, through blockade of PD-1 binding to PD ...
Cell-cycle nonspecific antineoplastic agents; Chemically linked Fab; Chemoimmunotherapy; Chemoprotective agent; Chemosensitizer; Chemotherapy; Chemotherapy-induced nausea and vomiting; Ciltacabtagene autoleucel; Copanlisib; Cytestrol acetate
The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. [5] [10]The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and ...
Desidustat is developed for the treatment of anemia as an oral tablet, where currently injections of erythropoietin and its analogues are drugs of choice. Desidustat is a HIF prolyl-hydroxylase inhibitor. In preclinical studies, effects of desidustat was assessed in normal and nephrectomized rats, and in chemotherapy-induced anemia.
Hydroxycarbamide is in the antineoplastic family of medications. It is believed to work by blocking the making of DNA. [4] Hydroxycarbamide was approved for medical use in the United States in 1967. [4] It is on the World Health Organization's List of Essential Medicines. [6] Hydroxycarbamide is available as a generic medication. [4]
Obinutuzumab has two black box warnings: hepatitis B reactivation and progressive multifocal leukoencephalopathy. [7] [5]In the clinical trial of obinutuzumab in combination with chlorambucil, participants experienced infusion reactions (69%; 21% grade 3/4), neutropenia (40%; 34% grade 3/4), thrombocytopenia (15%; 11% grade 3/4), anemia (12%), and pyrexia and cough (10% each).